Canada Markets close in 5 hrs 41 mins

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.2533+0.0089 (+3.64%)
As of 10:14AM EDT. Market open.
Currency in USD

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 310.1000
52 Week Low 30.2100
50-Day Moving Average 30.4220
200-Day Moving Average 31.5341

Share Statistics

Avg Vol (3 month) 3520.75k
Avg Vol (10 day) 3590.18k
Shares Outstanding 552.04M
Implied Shares Outstanding 6N/A
Float 831.56M
% Held by Insiders 126.39%
% Held by Institutions 132.65%
Shares Short (Jul 14, 2022) 42.23M
Short Ratio (Jul 14, 2022) 43.06
Short % of Float (Jul 14, 2022) 44.32%
Short % of Shares Outstanding (Jul 14, 2022) 43.88%
Shares Short (prior month Jun 14, 2022) 43.33M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:2
Last Split Date 3Mar 25, 2021

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Mar 30, 2022


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-65.25%
Return on Equity (ttm)-1,759.51%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -29.14M
Net Income Avi to Common (ttm)-113.41M
Diluted EPS (ttm)-0.4470
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)23.5M
Total Cash Per Share (mrq)0.41
Total Debt (mrq)1.17M
Total Debt/Equity (mrq)6.74
Current Ratio (mrq)6.82
Book Value Per Share (mrq)0.25

Cash Flow Statement

Operating Cash Flow (ttm)-25.49M
Levered Free Cash Flow (ttm)-12.8M